Literature DB >> 27064687

Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy.

W I Gonsalves1, S V Rajkumar1, M A Gertz1, A Dispenzieri1, M Q Lacy1, F K Buadi1, D Dingli1, R S Go1, N Leung1, P Kapoor1, S R Hayman1, J A Lust1, S J Russell1, S R Zeldenrust1, Y L Hwa1, T V Kourelis1, R A Kyle1, S K Kumar1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27064687     DOI： 10.1038/bmt.2016.91

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

Review 1.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

2.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Authors:  Sagar Lonial; Meletios Dimopoulos; Antonio Palumbo; Darrell White; Sebastian Grosicki; Ivan Spicka; Adam Walter-Croneck; Philippe Moreau; Maria-Victoria Mateos; Hila Magen; Andrew Belch; Donna Reece; Meral Beksac; Andrew Spencer; Heather Oakervee; Robert Z Orlowski; Masafumi Taniwaki; Christoph Röllig; Hermann Einsele; Ka Lung Wu; Anil Singhal; Jesus San-Miguel; Morio Matsumoto; Jessica Katz; Eric Bleickardt; Valerie Poulart; Kenneth C Anderson; Paul Richardson
Journal:  N Engl J Med       Date:  2015-06-02       Impact factor: 91.245

3.  Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

Authors:  Joaquin Martinez-Lopez; Joan Blade; María-Victoria Mateos; Carlos Grande; Adrián Alegre; José García-Laraña; Anna Sureda; Javier de la Rubia; Eulogio Conde; Rafael Martinez; Felipe de Arriba; Maria C Viguria; Joan Besalduch; Rafael Cabrera; José D Gonzalez-San Miguel; José Luis Guzman-Zamudio; Maria Carmen Gomez del Castillo; José Maria Moraleda; Juan C García-Ruiz; Jesús San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

4.  Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients' monitoring after transplantation.

Authors:  D Zamarin; S Giralt; H Landau; N Lendvai; A Lesokhin; D Chung; G Koehne; D Chimento; S M Devlin; E Riedel; M Bhutani; D Babu; H Hassoun
Journal:  Bone Marrow Transplant       Date:  2012-08-13       Impact factor: 5.483

5.  Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma.

Authors:  C Fernández de Larrea; R Jiménez; L Rosiñol; E Giné; N Tovar; M T Cibeira; F Fernández-Avilés; C Martínez; M Rovira; J Bladé
Journal:  Bone Marrow Transplant       Date:  2013-09-30       Impact factor: 5.483

6.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Authors:  A Keith Stewart; S Vincent Rajkumar; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Georgi G Mihaylov; Vesselina Goranova-Marinova; Péter Rajnics; Aleksandr Suvorov; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Michael Wang; Vladimír Maisnar; Jiri Minarik; William I Bensinger; Maria-Victoria Mateos; Dina Ben-Yehuda; Vishal Kukreti; Naseem Zojwalla; Margaret E Tonda; Xinqun Yang; Biao Xing; Philippe Moreau; Antonio Palumbo
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

7.  Impact of early relapse after auto-SCT for multiple myeloma.

Authors:  S Kumar; S T Mahmood; M Q Lacy; A Dispenzieri; S R Hayman; F K Buadi; D Dingli; S V Rajkumar; M R Litzow; M A Gertz
Journal:  Bone Marrow Transplant       Date:  2008-06-30       Impact factor: 5.483

8.  Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Laurent Garderet; Simona Iacobelli; Philippe Moreau; Mamoun Dib; Ingrid Lafon; Dietger Niederwieser; Tamas Masszi; Jean Fontan; Mauricette Michallet; Alois Gratwohl; Giuseppe Milone; Chantal Doyen; Brigitte Pegourie; Roman Hajek; Philippe Casassus; Brigitte Kolb; Carine Chaleteix; Bernd Hertenstein; Francesco Onida; Heinz Ludwig; Nicolas Ketterer; Christian Koenecke; Marleen van Os; Mohamad Mohty; Andrew Cakana; Norbert Claude Gorin; Theo de Witte; Jean Luc Harousseau; Curly Morris; Gösta Gahrton
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

9.  Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.

Authors:  Prashant Kapoor; Shaji K Kumar; Angela Dispenzieri; Martha Q Lacy; Francis Buadi; David Dingli; Stephen J Russell; Suzanne R Hayman; Thomas E Witzig; John A Lust; Nelson Leung; Yi Lin; Steven R Zeldenrust; Arleigh McCurdy; Philip R Greipp; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

10.  Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors:  Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245
View more
  7 in total

Review 1.  The next generation of novel therapies for the management of relapsed multiple myeloma.

Authors:  Wilson I Gonsalves; Paolo Milani; Daniel Derudas; Francis K Buadi
Journal:  Future Oncol       Date:  2016-08-11       Impact factor: 3.404

2.  The impact of response kinetics for multiple myeloma in the era of novel agents.

Authors:  Yuting Yan; Xuehan Mao; Jiahui Liu; Huishou Fan; Chenxing Du; Zengjun Li; Shuhua Yi; Yan Xu; Rui Lv; Wei Liu; Shuhui Deng; Weiwei Sui; Qi Wang; Dehui Zou; Jianxiang Wang; Tao Cheng; Fenghuang Zhan; Yu-Tzu Tai; Chenglu Yuan; Xin Du; Lugui Qiu; Kenneth C Anderson; Gang An
Journal:  Blood Adv       Date:  2019-10-08

3.  The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma.

Authors:  Toshi Ghosh; Wilson I Gonsalves; Dragan Jevremovic; Angela Dispenzieri; David Dingli; Michael M Timm; William G Morice; Prashant Kapoor; Taxiarchis V Kourelis; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Nelson Leung; Ronald S Go; Yi Lin; Stephen J Russell; John A Lust; Steven R Zeldenrust; Rahma Warsame; Yi L Hwa; Robert A Kyle; Morie A Gertz; S Vincent Rajkumar; Shaji K Kumar
Journal:  Am J Hematol       Date:  2017-07-19       Impact factor: 10.047

4.  Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.

Authors:  Pilar de la Puente; Micah J Luderer; Cinzia Federico; Abbey Jin; Rebecca C Gilson; Christopher Egbulefu; Kinan Alhallak; Shruti Shah; Barbara Muz; Jennifer Sun; Justin King; Daniel Kohnen; Noha Nabil Salama; Samuel Achilefu; Ravi Vij; Abdel Kareem Azab
Journal:  J Control Release       Date:  2017-11-28       Impact factor: 9.776

5.  The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center.

Authors:  Laura A Evans; Ronald Go; Rahma Warsame; Bharat Nandakumar; Francis K Buadi; Angela Dispenzieri; David Dingli; Martha Q Lacy; Suzanne R Hayman; Prashant Kapoor; Nelson Leung; Amie Fonder; Miriam Hobbs; Yi Lisa Hwa; Eli Muchtar; Taxiarchis V Kourelis; Stephen Russell; John A Lust; Yi Lin; Mustaqeem Siddiqui; Robert A Kyle; Morie A Gertz; S Vincent Rajkumar; Shaji Kumar; Wilson I Gonsalves
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2021-02-17

Review 6.  Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

Authors:  Wilson I Gonsalves; Francis K Buadi; Sikander Ailawadhi; P Leif Bergsagel; Asher A Chanan Khan; David Dingli; Angela Dispenzieri; Rafael Fonseca; Susan R Hayman; Prashant Kapoor; Taxiarchis V Kourelis; Martha Q Lacy; Jeremy T Larsen; Eli Muchtar; Craig B Reeder; Taimur Sher; A Keith Stewart; Rahma Warsame; Ronald S Go; Robert A Kyle; Nelson Leung; Yi Lin; John A Lust; Stephen J Russell; Stephen R Zeldenrust; Amie L Fonder; Yi L Hwa; Miriam A Hobbs; Angela A Mayo; William J Hogan; S Vincent Rajkumar; Shaji K Kumar; Morie A Gertz; Vivek Roy
Journal:  Bone Marrow Transplant       Date:  2018-07-09       Impact factor: 5.483

7.  Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.

Authors:  Cinzia Federico; Kinan Alhallak; Jennifer Sun; Kathleen Duncan; Feda Azab; Gail P Sudlow; Pilar de la Puente; Barbara Muz; Vaishali Kapoor; Luna Zhang; Fangzheng Yuan; Matea Markovic; Joseph Kotsybar; Katherine Wasden; Nicole Guenthner; Shannon Gurley; Justin King; Daniel Kohnen; Noha N Salama; Dinesh Thotala; Dennis E Hallahan; Ravi Vij; John F DiPersio; Samuel Achilefu; Abdel Kareem Azab
Journal:  Nat Commun       Date:  2020-11-27       Impact factor: 14.919
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.